Our Leadership Team

Mark W. Womack is an organization builder with a track record of delivering unprecedented growth and profit in every role.

Mark is BioCina’s Chief Executive Officer, and in his first 9 months at the helm he led BioCina to a 500% YOY increase in sales and a 250% YOY increase in revenue. On February 1, 2024, he was also appointed to the Board of Directors for both NovaCina and LumaCina. In January of 2025, BioCina and NovaCina announced a strategic merger that will create a powerful brand in biopharmaceutical and small molecule contract manufacturing. The combined company will retain the BioCina name and Mark is continuing as CEO.

Prior to BioCina, as CEO of KBI Biopharma and Selexis SA, Mr. Womack led the company to a run rate of over a 30% YOY revenue increase in only 6 months. Previous to that, as CEO of Stelis Biopharma, he led Stelis to build and qualify a state-of-the-art vaccine facility in record time, while also generating over $200M in new sales.

Preceding Stelis, as the CBO for AGC Biologics, one of the world’s leading global biopharma CDMO’s, Mr. Womack led the organization to nearly a 300% increase in new sales in just two years and drove the acquisition of many of the top Large Pharma companies into the AGC Biologics Client portfolio.

Prior to joining AGC Biologics, Mr. Womack served over 20 years as a management consulting industry leader and C-level client advisor, guiding many of the world’s renowned companies to achieve record highs in revenue and profit. He joined the management consulting industry with Capgemini as a Principal and within three years became a leader of large-scale transformations, including a $20B post-merger integration within General Motors. In 2001, Mr. Womack became EVP, Head of Consulting Operations—Americas, for Celerant Consulting. In 2003, he founded his own boutique executive management consultancy, J.W. Webb Inc. For 11 years, J.W. Webb served elite clients such as Bayer HealthCare, CMC Biologics, Coors Brewing Company, and Whirlpool.

Mr. Womack began his professional journey by leading a succession of U.S. Navy units to unprecedented results, including while serving as a combat center leader on a destroyer class ship. During his military career, he was honored with numerous of the Navy’s highest honors and awards. Mr. Womack has been quoted as a key source in The New York Times, Fast Company and many other major global media outlets.

Anthony Chhoy is a strategic finance leader with 25 years of global experience in driving growth, transformation, and operational excellence across start-ups and multinational enterprises. As Chief Financial Officer of BioCina, he leads financial strategy, scalability, and operational efficiency, ensuring BioCina remains a trusted CDMO partner for biotech and pharmaceutical innovators worldwide.

Anthony has a proven track record of scaling businesses, optimizing financial performance, and navigating complex market landscapes. From leading a technology start-up that empowered over 4 million students globally to steering a Nasdaq-listed media company with $750M in revenue and 4,500 employees across six countries, his expertise in financial discipline, transformation, and strategic growth has been instrumental in driving business success—including leading the company through its acquisition by Time Warner.

Beginning his career at Arthur Andersen, then one of the Big Five accounting firms, Anthony built a strong foundation in financial leadership and business strategy. Now at BioCina, he plays a pivotal role in financial stewardship, strategic expansion, and operational excellence, ensuring the company continues its trajectory as the most client-centric and reliable CDMO in the industry.

Jason Arcediano brings an impressive 30 years of experience in the biologics industry to BioCina. As Chief Commercial Officer, he leads global business development, strategic partnerships, and commercial expansion, ensuring BioCina continues to serve as a trusted CDMO partner for biotech and pharmaceutical innovators worldwide.

Jason has a wealth of expertise in global biopharmaceutical operations, corporate development, strategy, licensing, M&A, alliance management, executive management, business development, and marketing. His scientific background and extensive industry experience uniquely position him to understand both the technical and commercial aspects of the CDMO industry and what clients value most.

Prior to joining BioCina, Jason served as Chief Business Officer and Commercial Advisor at Multiply Labs, where he played a key role in advancing robotics-driven manufacturing solutions for precision medicine. His career also includes senior leadership roles at Lonza, Rentschler Biopharma, and AGC Biologics, where he was instrumental in driving business growth, strategic partnerships, and operational excellence.

Jason holds a Bachelor of Science in Neuroscience from the University of California, San Diego. His deep knowledge of the biotech landscape, combined with his strategic leadership, will be instrumental in elevating BioCina’s commercial efforts and driving its ambitious growth vision.

Michael Tsaconas is BioCina’s Vice President and General Manager. Michael is a seasoned executive with more than 20 years experience in pharmaceutical manufacturing of liquids, creams, solid oral dose forms and large molecule drug substance at companies including FH Faulding, Mayne Pharma, Hospira and most recently Pfizer.

Michael has worked in the areas of Quality Control, Quality Assurance, Operational Excellence and Operations. He has had significant exposure to all aspects of Good Manufacturing Practice (GMP) and experience in the oversight of facilities that manufacture for highly regulated markets. Michael has been involved with manufacturing operations that have taken programs from development through to commercial manufacture. He was responsible for Pfizer’s Adelaide operations that achieved FDA approval for a biosimilar product in 2020.

Michael is a hands-on professional with a demonstrated strength and passion for change management and a strategic focus on building and supporting high performing teams to achieve business outcomes that generate value and growth.

Michael is from Adelaide, Australia and holds a Bachelor of Science (Hons) from Flinders University.

Jan Bekker is BioCina’s Vice President Business Development and Commercial Operations. Jan is a biopharmaceutical industry professional with over 20 years academic and industry experience with previous roles at Pfizer, Hospira, Centre for Marine Bioproducts Development, Stellenbosch University, and the Queensland University of Technology.

Jan’s significant industry experience and technical knowledge allows him to tailor programs that deliver on customer requirements. Jan has a depth of knowledge in program design that includes pre-clinical, clinical, and commercial manufacturing.

He brings a true end-to-end approach to BioCina’s Business Development capabilities.

Jan received his PhD from Stellenbosch University and his MBA from the University of New South Wales’s Australian Graduate School of Management.

Anthony Morgan is BioCina’s Director of Operations. Anthony is a seasoned professional with 23 years of experience in the biopharmaceutical manufacturing industry, including Life Technologies, Invitrogen, Hospira and Pfizer. He has held positions in project management, business development, leading manufacturing operations and general management of operations and facilities.

Anthony’s broad experience and strong project management background drives BioCina’s Operations to focus on both cGMP compliance and manufacturing efficiency to support the delivery of successful client programs.

Anthony holds a Bachelor of Science, Plant and Microbial Sciences, from the University of Canterbury and has qualifications in Biochemistry and Project Management.

Melissa El Khouri is BioCina’s Head of Quality. Melissa drives for right-sized quality processes, to maintain the highest quality standards and cost-effective service. Melissa has over 10 years of experience in Quality, including previous roles at Hospira and Pfizer.

Her strong engineering and validation technical skills support her quality decision making and support of management of BioCina’s CDMO client portfolio.

Melissa has experience in designing and managing quality management systems that meet the regulatory requirements of highly regulated markets including, but not limited to, USFDA, EMA and the Australian TGA.

Melissa managed a successful USFDA Pre-Approval Inspection (PAI) in 2019, that resulted in a product approval in 2020.

Melissa holds a Bachelor of Pharmaceutical Engineering, from the University of Adelaide and a master’s degree in Engineering Management, from the University of Technology Sydney. She also volunteers as a committee member and representative for South Australia of the PDA Australia Chapter.

Jane Slobedman is BioCina’s Associate Director of Program Management. Jane has more than 25 years of experience in the Pharma industry, spending the last 13 years working as a program manager for biopharmaceutical projects, partnering with in-house and CDMO clients to bring projects from early-stage development to commercialisation.

Jane has worked in both drug product and drug substance manufacturing facilities and has significant experience in managing CDMO projects, working for leading pharmaceutical companies including Pfizer, Hospira and Mayne Pharma.

Jane’s passion is delivering programs that generate positive outcomes for clients and most importantly the patients that can benefit from the products BioCina manufactures.

Jane has an Honours degree in Chemical Engineering from Adelaide University.